These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 235639)

  • 1. Further properties of stereospecific opiate binding sites in rat brain: on the nature of the sodium effect.
    Simon EJ; Hiller JM; Groth J; Edelman I
    J Pharmacol Exp Ther; 1975 Mar; 192(3):531-7. PubMed ID: 235639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solubilization and preliminary characterization of mu and kappa opiate receptor subtypes from rat brain.
    Chow T; Zukin RS
    Mol Pharmacol; 1983 Sep; 24(2):203-12. PubMed ID: 6310362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereospecific binding of the potent narcotic analgesic (3H) Etorphine to rat-brain homogenate.
    Simon EJ; Hiller JM; Edelman I
    Proc Natl Acad Sci U S A; 1973 Jul; 70(7):1947-9. PubMed ID: 4516196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Opiate receptor binding of naloxone in the rat brain: effect of sodium ions].
    Balashov AM; Petrichenko OB; Aliab'eva TN; Panchenko LF
    Biokhimiia; 1988 Sep; 53(9):1527-31. PubMed ID: 2849481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
    Liu-Chen LY; Yang HH; Li S; Adams JU
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of pH on stereospecific opiate binding to mouse brain membranes.
    Smith AP
    Res Commun Chem Pathol Pharmacol; 1977 Jul; 17(3):375-98. PubMed ID: 19822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of stereospecific binding of the potent narcotic analgesic etorphine in the human brain: predominance in the limbic system.
    Hiller JM; Pearson J; Simon EJ
    Res Commun Chem Pathol Pharmacol; 1973 Nov; 6(3):1052-62. PubMed ID: 4760880
    [No Abstract]   [Full Text] [Related]  

  • 8. Identification of opiate/receptor binding in vivo.
    Höllt V; Haarmann I; Herz A
    Arzneimittelforschung; 1976; 26(6):1102-4. PubMed ID: 989388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity of opioid receptor binding in brain slices.
    Barchfeld-Rothschild CC; Medzihradsky F
    J Neurosci Res; 1987; 18(2):358-65. PubMed ID: 2891857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative film autoradiography of opiate agonist and antagonist binding in rat brain.
    Geary WA; Wooten GF
    J Pharmacol Exp Ther; 1983 Apr; 225(1):234-40. PubMed ID: 6300375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decrease in delta and mu opioid receptor binding capacity in rat brain after chronic etorphine treatment.
    Tao PL; Law PY; Loh HH
    J Pharmacol Exp Ther; 1987 Mar; 240(3):809-16. PubMed ID: 3031275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-affinity dextromethorphan binding sites in guinea pig brain. I. Initial characterization.
    Craviso GL; Musacchio JM
    Mol Pharmacol; 1983 May; 23(3):619-28. PubMed ID: 6408390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine: differential interaction with opiate receptor subtypes in vivo.
    Sadée W; Rosenbaum JS; Herz A
    J Pharmacol Exp Ther; 1982 Oct; 223(1):157-62. PubMed ID: 6288917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
    Zhao GM; Qian X; Schiller PW; Szeto HH
    J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium regulation of agonist binding at opioid receptors. II. Effects of sodium replacement on opioid binding in guinea pig cortical membranes.
    Werling LL; Brown SR; Puttfarcken P; Cox BM
    Mol Pharmacol; 1986 Aug; 30(2):90-5. PubMed ID: 3016504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-(3-Fluoropropyl)-N-normetazocine, a potentially useful opiate antagonist for opiate receptor studies with positron emission tomography (PET).
    Feliu AL; Holland MJ; Carr KD; Fowler JS; Simon EJ
    Res Commun Chem Pathol Pharmacol; 1985 Sep; 49(3):323-36. PubMed ID: 2997887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [3H]-[H-D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2] ([3H]CTOP), a potent and highly selective peptide for mu opioid receptors in rat brain.
    Hawkins KN; Knapp RJ; Lui GK; Gulya K; Kazmierski W; Wan YP; Pelton JT; Hruby VJ; Yamamura HI
    J Pharmacol Exp Ther; 1989 Jan; 248(1):73-80. PubMed ID: 2563293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
    Sterious SN; Walker EA
    J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etorphine binds to multiple opiate receptors of the caudate nucleus with equal affinity but with different kinetics.
    Tolkovsky AM
    Mol Pharmacol; 1982 Nov; 22(3):648-56. PubMed ID: 6296657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anatomical distribution of sodium-dependent [(3)H]naloxone binding sites in rat brain.
    Sim-Selley LJ; Xiao R; Childers SR
    Synapse; 2000 Mar; 35(4):256-64. PubMed ID: 10657035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.